Abstract
Physical interaction between CDKN2A/p16 and CDK4 proteins regulates the cell cycle progression through the G1 phase and dysfunction of these proteins by gene mutation is implicated in genetic predisposition to melanoma. We analysed 15 Italian melanoma families for germ line mutations in the coding region of the CDKN2A gene and exon 2 of the CDK4 gene. One novel disease-associated mutation (P48T), 3 known pathological mutations (R24P, G101W and N71S) and 2 common polymorphisms (A148T and Nt500 G>C) were identified in the CDKN2A gene. In a family harbouring the R24P mutation, an intronic variant (IVS1, +37 G>C) of uncertain significance was detected in a non-carrier melanoma case. The overall incidence of CDKN2A mutations was 33.3%, but this percentage was higher in families with 3 or more melanoma cases (50%) than in those with only 2 affected relatives (25%). Noteworthy, functional analysis established that the novel mutated protein, while being impaired in cell growth and inhibition assays, retains some in vitro binding to CDK4/6. No variant in the p16-binding region of CDK4 was identified in our families. Our results, obtained in a heterogeneous group of families, support the view that inactivating mutations of CDKN2A contribute to melanoma susceptibility more than activating mutations of CDK4 and that other genetic factors must be responsible for melanoma clustering in a high proportion of families. In addition, they indicate the need for a combination of functional assays to determine the pathogenetic nature of new CDKN2A mutations. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912–915
Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H and Ingvar C (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92: 1260–1266
Brotherton DH, Dhanaraj V, Wick S, Brizuela L, Domaille PJ, Volyanik Xu X, Parisini E, Smith BO, Archer SJ, Serrano M, Brenner SL, Blundell TL and Laue ED (1998) Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 395: 244–250
Castellano M and Parmiani G (1999) Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res 9: 421–432
Coleman K, Wautlet B, Morrissey D, Mulheron J, Sedman S, Brinkley P, Price S and Webster K (1997) Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 272: 18869–18874
Delia D, Goi K, Mizutani S, Yamada T, Aiello A, Fontanella E, Lamorte G, Iwata S, Ishioka C, Krajewski S, Reed CC and Pierotti MA (1997) Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 14: 2137–2147
Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G and Pierotti MA (1993) Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753–1760
Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, Ajmar F, Bruzzi P and Bianchi-Scarra G (1999) Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 83: 441–448
Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC and Clark WH Jr et al (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. New Engl J Med 333: 970–974
Goldstein AM, Struewing J, Chidambaram A, Fraser MC and Tucker MA (2000) Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92: 1006–1010
Greene MH and Fraumeni JF Jr (1979) The hereditary variant of malignant melanoma. In Human Malignant Melanoma, Clark WHJr, Goldman LI, Mastangelo MJ (eds) pp 139–166. New York, NY, Grune Stratton
Guldberg P, Kirkin AF, Gronbaek K, thor Straten P, Ahrenkiel V and Zeuthen J (1997) Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 72: 780–783
Haluska FG and Hodi FS (1998) Molecular genetics of familial cutaneous melanoma. J Clin Oncol 16: 670–682
Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT and Bishop JN (1997) Germine mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6: 2061–2067
Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BAJ, Mann GJ and Bishop DT et al (2000) Mutation screening of the CDKN2A promoter in melanoma families. Genes Chrom Cancer 28: 45–57
Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, Kefford RF and Mann GJ (1995) Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11: 2289–2294
Holland EA, Schmid H, Kefford RF and Mann GJ (1999) CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chrom Cancer 25: 339–348
Koh J, Enders GH, Dynlacht BD and Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506–510
Lilischkis R, Sarcevic B, Kennedy C, Warlters A and Sutherland RL (1996) Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66: 249–254
Morgenstern JP and Land H (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucl Acids Res 18: 3587–3596
Parry D and Peters G (1996) Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16: 3844–3852
Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D and Dracopoli NC (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10: 114–116
Ruas M and Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Bioch Biophys Acta 1378: F115–F177
Ruas M, Brookes S, McDonald NQ and Gordon P (1999) Functional evaluation of tumor-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene 18: 5423–5434
Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, Puig L, Sanchez-Conejo J, Estivill X and Castel T (1999) CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 36: 490–493
Soufir N, Avril MF, Chompret A, Demenais F, Bpmbled J, Spatz A, Stoppa-Lyonnet D, French Familial Melanoma Study Group Benard J and Bressac-de Paillerets B (1998) Prevalence of p16 and CDk4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7: 209–216
Tsao H, Benoit E, Sober AJ, Thiele C and Haluska FG (1998) Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 58: 109–113
Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zBK and Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281–1284
Yarbrough WG, Aprelikova O, Pei H, Olshan AF and Liu ET (1996) Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 88: 1489–1491
Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ & Hayward Dracopoli NC (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97–99
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Torre, G., Pasini, B., Frigerio, S. et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85, 836–844 (2001). https://doi.org/10.1054/bjoc.2001.1991
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1991
Keywords
This article is cited by
-
Identification of BRAF, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature
World Journal of Surgical Oncology (2023)
-
Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: A case report
Journal of Otolaryngology - Head & Neck Surgery (2022)
-
Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT
Journal of Investigative Dermatology (2009)
-
Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye
The EMBO Journal (2005)
-
DNA sequence and analysis of human chromosome 9
Nature (2004)